Therefore, we selected MHCC97L and MHCC97H for follow-up studies. Fascinatingly, sorafenib dosage demonstrated a proportional suppression of the PLAG1 level in HCC cell lines MHCC97H and MHCC97L suggesting its potential to combat PLAG1 expressions in HCC progression (Fig. 1H). Here, PLAG1 is linked to hepatocellular carcinoma.